Simvastatin Plus Dual Anti-HER2 Therapy for Metastatic Breast Cancer (SIMPHONY)

  • STATUS
    Recruiting
  • End date
    Dec 18, 2030
  • participants needed
    34
  • sponsor
    Baylor Breast Care Center
Updated on 18 April 2022
platelet count
ejection fraction
measurable disease
breast cancer
endocrine therapy
metastasis
hormone therapy
HER2
adenocarcinoma

Summary

This study recruits patients with metastatic breast cancer who have progressed on their current regimen of dual anti-HER2 therapy. This study evaluates whether or not the addition of simvastatin to the dual anti-HER2 therapy regimen helps make the tumor respond to the anti-HER2 therapy again. All participants will receive simvastatin in combination with their current anti-HER2 therapy regimen.

Description

This study is recruiting participants with metastatic breast cancer that is HER2 positive. "Metastatic" means that cancer has spread to areas of the body outside of the breast. "HER2 positive" means that a cancer cell has too many HER2 receptors on its surface. HER2 receptors act like copy machines, and help tell cancer cells to grow and multiply.

Drugs known as HER2-targeted therapies are often used to treat HER2-positive cancers. HER2-targeted therapies work by blocking the HER2 protein from telling the cell to grow and divide. Once the protein stops working, the cancer cells can no longer make copies of themselves. Once a cancer cell becomes unable to make copies of itself, the tumor will start to shrink. However, some tumors are able to find other ways to make copies of themselves, even when the HER2 protein is blocked. When this happens, the cancer will start to grow again. Researchers believe that adding a drug called simvastatin to an anti-HER2 therapy regimen may cause the cancer to start responding again to your HER2-medications.

Simvastatin is a drug that is approved by the Food and Drug Administration (FDA) to treat high cholesterol. Laboratory research has shown that simvastatin together with dual HER2-targeted therapy slows the growth of breast cancer tumors that had been growing on dual HER2-targeting therapy alone.

Details
Condition Breast Cancer Stage IV
Treatment simvastatin 40mg, Simvastatin 80mg
Clinical Study IdentifierNCT03324425
SponsorBaylor Breast Care Center
Last Modified on18 April 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

Signed informed consent
Patients must have histologically confirmed and documented adenocarcinoma of the breast with metastatic disease not amenable to curative therapy
Cancer must be HER2-positive, according to ASCO-CAP guidelines. Any ER and PR status is allowed
Participants must have documented disease progression while receiving dual anti-HER2 targeted therapy for metastatic breast cancer, as per investigator assessment. Any combination of biologic therapies is acceptable. Prior chemotherapy is acceptable, but patients must have been off cytotoxic chemotherapy for at least 1 month. Patients with ER-/HER2+ disease have must be failed at least 1 line of chemotherapy in the metastatic setting. Patients with ER+/HER2+ disease who progressed on dual anti-HER2 therapy plus endocrine therapy are eligible. Concomitant endocrine therapy is acceptable and may be continued at the discretion of the treating physician
Patient must be female and at least 18 years of age
Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤ 2
Patients must have measurable disease, per RECIST criteria v1.1.21
Participants must not have undergone major surgery or radiation therapy within 28 days prior to beginning treatment with simvastatin. Any toxicity from prior surgical or radiation treatment must have sufficiently resolved prior to study entry, as determined by the treating physician
Estimated life expectancy of ≥ 12 weeks
Ability to swallow oral medications
Participants must have adequate organ function as defined by
ANC ≥1.5 x 109/L, platelet count ≥100 x 109/L, haemoglobin ≥ 10 g/dL
creatinine < 1.5 x UNL (upper normal limit)
Total bilirubin < 1.5x UNL
ALT & AST < 2.5xUNL; alkaline phosphatase < 2.5xUNL
Creatine phosphokinase (CPK) ≤ 2.5 x UNL
Baseline left ventricular ejection fraction (LVEF) ≥ 50% as determined by either
echocardiography (ECHO) or multi gated acquisition (MUGA) scan
Patients with CNS metastatic disease are allowed if the disease is controlled and stable for at least 3 months by CT or MRI
Negative pregnancy test within 7 days prior to study treatment start, for women of childbearing potential. Women of childbearing potential must agree to use an adequate form of contraception for the duration of their study participation

Exclusion Criteria

Patients currently treated with a statin or who have been treated with a statin in the past 2 months are ineligible for this study
Known hypersensitivity to statins
Prior history of rhabdomyolysis
Patients who consume more than 3 alcoholic beverages per day
Lack of physical integrity of the upper gastrointestinal tract, clinically significant malabsorption syndrome, or inability to take oral medications
Current severe, uncontrolled systemic disease (e.g. pulmonary, or metabolic disease; wound healing disorders; ulcers; or bone fractures)
Poorly controlled hypertension at the physician's discretion or clinically significant (i.e. active) cardiovascular disease: cerebrovascular accident (CVA) / stroke within ≤ 6 months prior to the first study treatment, myocardial infarction within ≤ 6 months prior to the first study treatment, unstable angina, New York Heart Association (NYHA) grade II or greater congestive heart failure (CHF), or serious cardiac arrhythmia requiring medication
Current or past infection with Human Immunodeficiency Virus (HIV), Hepatitis B virus (HBV), or Hepatitis C virus (HCV)
Receipt of IV antibiotics for infection within 7 days of study enrollment
History of other malignancies within the last 2 years, except for carcinoma in situ of the cervix or basal cell carcinoma
Participants with bone-only disease are excluded, unless a measureable lesion is present, as defined by RECIST 1.1
Patients who suffer from a medical or psychiatric condition that, in the opinion of the principal investigator, would impair their ability to participate in the study
Concurrent interventional studies
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note